Scarica l'app Stockscreener
52.21
0.61%
-0.32
Dopo l'orario di chiusura:
52.60
0.39
+0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN
TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Merck gains U.S. patent office support in Keytruda dispute - MSN
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus
Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance
Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance
Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus
Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook - GuruFocus
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey
(HALO) Investment Report - news.stocktradersdaily.com
Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World
Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal
Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK
Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus
Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise
Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail
Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus
Breakthrough: EU Approves 5-Minute Cancer Treatment Option Using Halozyme's Technology - Stock Titan
High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance
New Strong Buy Stocks for May 28th - The Globe and Mail
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World
Halozyme downgraded at Morgan Stanley on price control risk - MSN
Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance
Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):